The inhibitory effects of ribociclib on the Rb pathway observed only in sensitive but not resistant RCC cells clearly indicate that ribociclib acts on RCC cells through inhibiting the CDK4/6-cyclin D-pRb signaling. This evidence concerns the gene CDK4 and renal cell carcinoma.